Arrowhead Pharmaceuticals, Inc. (ARWR)
ARWR Price and Sentiment
ARWR Latest news
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals to Participate in Upcoming September 2021 Conferences
Arrowhead Pharmaceuticals is a leading innovator in promising drugs to treat crippling diseases. This piece focuses on its two most advanced liver disease drugs in trial, which also form the practical core of two key partnerships.
With the trading day more than halfway over, the broad markets were somewhat mixed.
Arrowhead Pharmaceuticals, Inc. (ARWR) CEO Christopher Anzalone on Q3 2021 Results - Earnings Call Transcript2021-08-06 00:11
Arrowhead Pharmaceuticals, Inc. (ARWR) CEO Christopher Anzalone on Q3 2021 Results - Earnings Call Transcript
Shares of Arrowhead Pharmaceuticals (NASDAQ:ARWR) were flat in after-market trading after the company reported Q3 results. Quarterly Results Earnings per share were down 123.08% year over year to ($0.29), which missed the estimate of ($0.20).
Arrowhead Pharmaceuticals Receives Breakthrough Therapy Designation from U.S. FDA for ARO-AAT for the Treatment of Alpha-1 Antitrypsin Deficiency Associated Liver Disease2021-07-29 07:30
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead receives breakthrough therapy designation for ARO-AAT and announces full enrollment for SEQUOIA Phase 2 clinical trial
This biotech underdog offers more than meets the eye.
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead host a webcast and conference call on August 5, 2021, at 4:30 p.m. ET to discuss fiscal 2021 third quarter results
The stock price of Arrowhead, a biopharmaceutical company that develops RNA interference therapies, has seen a large 30% fall over the last five trading days. The decline came after the company decided to pause its early stage clinical trials for AROENaC1001, the company's investigational treatment.